A century ago, the ketogenic diet was a standard of care in diabetest, used to prolong the life of children with type 1 diabetes and to control the symptoms of type 2 diabetes in adults (1). Because all forms of diabetes share a basic pathophysiological problem, carbohydrate intolerance, restriction of carbohydrate on a ketogenic diet (typically ≤50 g/d with >70% fat) often produced rapid and remarkable clinical improvement. Discovery of insulin in the 1920s enabled people with diabetes to control hyperglycemia on high-carbohydrate diets. However, the human toll and economic burden from diabetes complications continue to mount, despite increasingly sophisticated insulin analogs and drugs for associated conditions such as dyslipidemia, hypertension, and coagulopathy. Contrary to expectation, adoption of a higher-carbohydrate (lower-fat) diet by the US public in the second half of the 20th century could have contributed to the increasing prevalence of obesity (2), a major risk factor for type 2 diabetes. Despite commonly voiced concerns about the safety of, and lack of supporting evidence for, this putative fad (3), the ketogenic diet has a long track record—not only in clinical medicine but also through human evolution—providing evidence for optimism in the search for more effective dietary prevention and treatment of chronic diseases.

Carbohydrate Restriction Is More Effective than Fat Restriction for Obesity Treatment

For decades, dietary fat was considered uniquely fattening due to its high energy density and palatability, leading to “passive overconsumption” relative to all carbohydrates (4). However, recent research underscores a biological basis for body weight control, by which the metabolic effects of food, more so than calorie content of specific foods or nutrients, determine body weight over the long term. According to the carbohydrate-insulin model of obesity (5, 6) the processed carbohydrates (e.g., most breads, rice, potato products, and added sugar) that replaced dietary fats during the low-fat diet era promote fat storage, increase hunger, and lower energy expenditure, predisposing to obesity and diabetes in susceptible individuals.

Most clinical trials comparing macronutrient-varying diets have employed low-intensity interventions, insufficient to produce significant long-term dietary change. Therefore, it is
not surprising that meta-analyses of these trials would show little long-term weight loss, and little difference between diet groups. Even so, meta-analyses have found that conventional low-fat diets are inferior to all higher-fat comparisons including ketogenic diets (7–10).

Anecdotal reports for many years have suggested that low-carbohydrate diets suppress hunger to a greater degree than conventional approaches, taking rate of weight loss into account. For example, in a small clinical trial from the 1950s, female college students with high body weight were given calorie-restricted diets varying in carbohydrate-to-fat ratio. Students on the low-fat diet reported a “lack of ‘pep’ throughout most of the study... [and feeling] discouraged because they were always conscious of being hungry.” In contrast, those on the very-low-carbohydrate diet reported “satisfaction” and that “[h]unger between meals was not a problem,” even though they had lost more weight (11). In a more recent crossover study, 17 men with obesity consumed ad libitum for 4 wk very-low-carbohydrate (4%) or moderate-carbohydrate (35%) diets controlled for protein. The participants consumed less dietary energy, lost more weight, and reported less hunger on the very-low-carbohydrate diet (12). This effect could relate to the improved circulating metabolic fuel concentration observed in the late postprandial period on a low-glycemic-load diet, and also to advantageous changes in metabolic hormones (e.g., lower ghrelin) (13, 14).

Carbohydrate restriction can also increase energy expenditure, a major goal of obesity research conventionally sought with drugs and exercise (15). In a 20-wk weight-loss-maintenance feeding study with 164 participants, those assigned to a low- (20%) compared with a high- (60%) carbohydrate diet had higher energy expenditure (~200–250 kcal/d), with evidence of effect modification by insulin secretion as predicted by the carbohydrate-insulin model (13, 16). Although a meta-analysis (17) suggested no benefit of low-carbohydrate compared with low-fat diets for energy expenditure, most of the included studies were too short (median duration <1 wk) to exclude well-described transient metabolic adaptations (5, 18). Behavioral trials with more powerful interventions lasting ≥1–2 y, and feeding studies of ≥4 wk, will be needed to test the true efficacy of carbohydrate restriction and clarify mechanisms.

**Low-Carbohydrate Diets Show Promise for Diabetes Treatment**

The US NIH sponsored several large multicentered studies of low-fat diets, such as the Women’s Health Initiative dietary modification trial (prevention of diabetes as a secondary outcome) (19) and Look Ahead (prevention of cardiovascular disease (CVD) in people with diabetes as the primary outcome) (20). In both cases, the low-fat diet showed no benefit, even though the comparison groups were given lower-intensity interventions. The Diabetes Prevention Program intensive lifestyle intervention reduced incidence of type 2 diabetes among high-risk participants (21), but the multicomponent nature of the intervention (including calorie restriction, fat restriction, exercise, and behavior modification) makes attribution of effects to the low-fat diet problematic. Unfortunately, no comparable studies of very-low-carbohydrate diets have been conducted, but smaller trials and observational studies suggest promise.

A 2019 Consensus Report from the American Diabetes Association concluded that low-carbohydrate diets (including those that aim for nutritional ketosis) “are among the most studied eating patterns for type 2 diabetes” and that these “eating patterns, especially very-low-carbohydrate... have been shown to reduce [HbA1C] [glycated hemoglobin] and the need for antihyperglycemic medications” (22). In a pragmatic trial including 262 adults with type 2 diabetes assigned to a very-low-carbohydrate diet, mean weight loss was 11.9 kg and HbA1c decreased by 1.0%, even with substantial reductions in the use of hypoglycemic medications other than metformin (23). Few clinical trials have examined carbohydrate restriction in type 1 diabetes, possibly due in part to concerns about hypoglycemia and ketoacidosis. In a survey of 316 children and adults following a very-low-carbohydrate diet for type 1 diabetes, exceptional glycemic control (mean HbA1c = 5.7%), low rates of hypoglycemia and ketoacidosis, an overall healthful CVD risk profile, and high satisfaction with diabetes management were documented (24).

**Low-Carbohydrate Diets Might Lower CVD Risk despite High Saturated Fat Content**

Although LDL cholesterol—an established CVD risk factor—can increase on low-carbohydrate diets (25), in part due to high saturated fat content, lipoprotein size distribution can indicate a relatively lower risk, characterized by larger, more buoyant particles (26). Consistent with this possibility, individuals with isolated elevated LDL cholesterol, compared with those who also have high triglycerides and low HDL cholesterol, were at lower risk for coronary events and benefited less from statin therapy in the Scandinavian Simvastatin Survival Study (27). Indeed, there is precedent for reduced cardiovascular risk in the context of higher LDL cholesterol: treatment with sodium-glucose cotransporter 2 inhibitors (28). The mechanisms elicited by this drug class share similarity on the physiological, if not molecular, level with a ketogenic diet. Both shift substrate utilization from carbohydrates to lipids, cause ketosis, reduce glycemic excursions, lower insulin concentrations, produce weight loss, promote natriuresis, and lower blood pressure—actions that can counterbalance or attenuate any adverse cardiovascular effects of elevated LDL cholesterol.

Carbohydrate restriction benefits multiple components of the metabolic syndrome, a major CVD risk factor. A low-carbohydrate diet improves hyperglycemia, triglycerides, HDL cholesterol, small dense LDL subclass phenotype, oxidized plasma lipids, and hepatic steatosis, whereas a low-fat diet can adversely affect some of these components (26, 29–34).

The relation between dietary fat and mortality in observational research is controversial due to methodological challenges involving confounding, reverse causality, and effect modification (e.g., overall diet quality, physical activity level). In a high-quality, 2-cohort study, high intake of fat as a proportion of total energy was associated with reduced risk of premature death, although the type of dietary fat importantly modified risk: decreased with unsaturated fat and increased with saturated fat (35). However, the relation between saturated fat and mortality observed in a general population might not apply to those consuming a ketogenic diet due to exceptionally high rates of saturated fat oxidation and low rates of de novo lipogenesis (36). Demonstrating this point, serum saturated fat
| Condition                           | Proposed mechanisms                                    |
|------------------------------------|-------------------------------------------------------|
| Cancer (ancillary treatment)       | Warburg effect; reduced concentration of insulin and other growth-stimulating hormones and factors; immune modulation; reduced side effects of chemotherapy, radiation |
| Brain                              |                                                       |
| Breast                             |                                                       |
| Colon                              |                                                       |
| Endometrial                        |                                                       |
| Lymphoma                           |                                                       |
| Pancreaticobiliary                 |                                                       |
| Prostate                           |                                                       |
| Cardiovascular                     | Weight loss; reduced postprandial glycemia, insulinemia; anti-inflammatory effects of ketones |
| Chronic inflammation               |                                                       |
| Dyslipidemia                        |                                                       |
| Endothelial dysfunction             |                                                       |
| Insulin resistance                 |                                                       |
| Endocrine                          | Reduced postprandial glycemic excursions, lower insulin requirement As above; weight loss Reduced anabolic stimulation of adipose; partitioning of metabolic fuels Reduced postprandial glycemia, insulinemia; enhanced fat oxidation Microbiome; carbohydrate fermentation Neuroprotective effects of ketones through reduced inflammation, edema oxidative damage, apoptosis, amyloid deposition; neural energy metabolism; epigenetic effects; microbiome Reduced withdrawal symptoms; reduced craving and reward, mediated by nucleus accumbens; reduced neuroinflammation; neuronal metabolism; microbiome |
| Diabetes, type 1                   |                                                       |
| Diabetes, type 2                   |                                                       |
| Obesity                            |                                                       |
| Gastrointestinal                   | Fatty liver, nonalcoholic                              |
| Irritable bowel syndrome           |                                                       |
| Neurological                        |                                                       |
| Alzheimer disease                  |                                                       |
| Epilepsy                           |                                                       |
| Mild cognitive impairment          |                                                       |
| Multiple sclerosis                 |                                                       |
| Oxygen toxicity (underwater diving)|                                                       |
| Traumatic brain injury             |                                                       |
| Spinal cord injury                 |                                                       |
| Psychological/psychiatric          | Reduced withdrawal symptoms; reduced craving and reward, mediated by nucleus accumbens; reduced neuroinflammation; neuronal metabolism; microbiome |
| Alcoholism                         |                                                       |
| Autism spectrum disorder           |                                                       |
| Bipolar disorder                   |                                                       |
| Mood disorders                     |                                                       |
| Schizophrenia                      |                                                       |
| Well-being/quality of life         |                                                       |
| Miscellaneous                      | Exercise tolerance, physical performance              |
| Gangliosidoses                     | Improved access to metabolic fuels                    |
| Infectious endocarditis, diagnosis | Increased efficacy, reduced side effects of primary treatment |
| Lymphedema                         | Enhanced signal-to-noise ratio with 18F-FDG PET scan  |
| Obstructive sleep apnea            | Endothelial cell function; lymphatic transport        |
|                                   | Weight loss; decreased visceral fat                    |

1Listed on clinicaltrials.gov as “Not yet recruiting,” “Recruiting,” or “Active, not recruiting” as of July 31, 2019. 18F-FDG PET, [18F]fluoro-2-deoxyglucose positron emission tomography.
2List not exhaustive.

Chronic Ketosis Might Provide Unique Metabolic Benefits

Ketosis, an evolutionarily ancient metabolic pathway, might confer additional benefits, beyond those of prevailing high-fat diets, through modulation of the inflammasome, oxidative damage, histone acetylation, mitophagy, cellular redox state, and other mechanisms (38, 39). Ketones have been termed a “superfuel” for the brain (39), upon which infants can be especially dependent (40). Based on these pleiotropic actions, a ketogenic diet has been considered for a wide range of health conditions. The website clinicaltrials.com currently lists 85 planned or active trials of a ketogenic or low-carbohydrate diet for diseases of numerous organ systems, including cardiovascular, endocrine, gastrointestinal, neurological, and psychiatric (see Table 1). Additional trials have been completed but not yet published.

The metabolic effects of a ketogenic diet can have special relevance to oncology. Many cancers contain mitochondrial defects, making them reliant on glycolytic fermentation, an inefficient energy generation pathway compared with oxidative phosphorylation (41, 42). A ketogenic diet targeting this Warburg effect might starve cancer cells without toxicity to normal cells, by decreasing fasting and postprandial blood
glucose concentrations. Other mechanisms recruited by this diet include reduced secretion of insulin, a hormonal driver of some tumors, and ketones themselves, through metabolic signaling actions. Because blood glucose concentrations remain in the low-normal range, and other fermentable fuels are available (e.g., glutamine), a ketogenic diet would not be expected to cure cancer as a stand-alone treatment. However, this diet might act synergistically with other treatments, such as phosphoinositide 3-kinase inhibitors (43), and aid prevention, possibilities that warrant investigation.

In view of the potent effects of ketones in the brain, a ketogenic diet has also generated considerable interest for neurodegenerative and neuropsychiatric disorders. Preliminary reports suggest that patients with Alzheimer disease, characterized by central insulin resistance, show clinical improvement with a ketogenic formula or exogenous ketones (44, 45). After a brief transitional period (46), a ketogenic diet can also improve general mood, although findings vary among studies (47).

Ketogenic Diets Have a Long Track Record of Safety

Concern has been expressed about the safety of ketogenic diets (3) based on case reports of children with epilepsy describing gastrointestinal problems, nephrolithiasis, cardiac abnormalities, and poor growth, but these reports need to be interpreted cautiously for several reasons. First, the ketogenic diet used in this clinical context is typically more extreme (with ≥85% energy as fat) than would be recommended for virtually any other purpose. Second, patients with epilepsy can have other health problems or medication use predisposing to complications, for which the general public would not be at risk. Third, case reports inevitably involve major selection bias; the absence of widespread adverse events in public health surveillance, despite the popularity of the ketogenic diet today (e.g., 5 of the top 10 best-selling diet books on Amazon.com), provides considerable reassurance.

Furthermore, without adequate attention to food quality, any macronutrient-focused eating pattern can have adverse effects. A low-fat diet containing high amounts of sugar and other processed carbohydrates raises risk of fatty liver and metabolic syndrome; a vegan diet without adequate attention to key micronutrients can cause growth retardation in children. Public health guidelines do not discourage low-fat and plant-based diets, but instead focus on measures to encourage healthful versions of these eating patterns to minimize risk and maximize benefits. With the substantial evidence of benefit as described above, diets that restrict carbohydrate warrant the same consideration.

There Is No Human Requirement for Dietary Fiber or Carbohydrate

Some have argued that the greatest risk “of the ketogenic diet may be the one most overlooked: the opportunity cost of not eating high-fiber, unrefined carbohydrates” (3), pointing to a meta-analysis of observational studies finding protective associations of whole-grain intake with CVD, cancer, and total mortality (48). However, such studies can only address the relative healthfulness of a specific food compared with foods that would have otherwise been consumed. Although strong evidence indicates benefits of consuming whole grains instead of refined grains (the typical trade-off in populations with grain-based diets), a more relevant question to this debate is how whole grains compare with low-carbohydrate foods allowed on a ketogenic diet. Bearing on this issue, a recent meta-analysis of clinical trials found that diets high in whole grains, compared with control diets, had no overall effect on measures of body fatness; among the trials with “unhealthy individuals” (having diabetes, metabolic syndrome, or overweight/obesity), whole-grain consumption increased BMI (49).

Admittedly, high-carbohydrate diets have been consumed by some populations with low rates of obesity-related chronic disease (e.g., “blue zones” in Asia), although these have typically had high levels of occupational physical activity (e.g., subsistence farming) and limited total calorie availability. However, the health benefits of grain consumption among populations with highly prevalent obesity and insulin resistance have not been established. In fact, diets with virtually no carbohydrate (and therefore, no fiber) throughout most of the year have been consumed by humans—for example, Native Americans of the Great Plains, Laplanders, the Inuit, and other traditional hunter-gatherer societies in temperate and arctic climates—much longer than a low-fat, high-carbohydrate diet as adopted by grain-based agrarian societies.

Conclusions

Both low-fat and low-carbohydrate diets can produce adverse effects in susceptible individuals (the former especially so among those with insulin resistance, comprising the majority in the United States). However, beyond fatigue and other transitional symptoms upon initial adoption, a well-formulated ketogenic diet does not appear to have major safety concerns for the general population. Based on available evidence, a ketogenic diet can be considered a first-line approach for the treatment of obesity and type 2 diabetes. A ketogenic diet also holds promise for a range of other chronic, sometimes intractable, conditions associated with metabolic dysfunction, such as type 1 diabetes, steatohepatitis, neurodegenerative disease, and cancer.

However, the lack of high-quality clinical trials hinders scientific understanding and public health translation. Key unresolved questions warranting research priority include: How does LDL cholesterol elevation with carbohydrate restriction affect cardiovascular risk versus triglyceride elevation with fat restriction? Does the reduction of HbA1c in diabetes on a ketogenic diet translate into reductions in micro- and macrovascular disease? Are there uniquely susceptible populations (e.g., LDL cholesterol “hyperresponders”) or conditions (liver or kidney disease, pregnancy) for which a ketogenic diet would be relatively contraindicated? What is the efficacy of a ketogenic diet for weight loss compared with other approaches in trials incorporating powerful methods to facilitate long-term behavior change? Does chronic ketosis provide unique metabolic benefits, beyond those that can be obtained with less restrictive regimens, such as a low-glycemic index, moderate-carbohydrate diet?

Finally, it is worth noting that the ketogenic diet has elicited controversy, in part because conventional nutritional teaching has for years emphasized the harms of high total and saturated fat intakes. Polarization might have also arisen from the misconception that ketogenic diets require high intakes of animal products—engendering concern among those who advocate plant-based diets for health, ethical, or environmental reasons.
In fact, a ketogenic diet can be vegetarian (containing eggs and dairy products) or vegan, with plant-based fats (e.g., avocado, nuts, seeds, coconut, flax, olive oil), proteins (e.g., tofu, tempeh, seitan, lupini beans, pea protein), nonstarchy vegetables, and limited amounts of low-sugar fruits, as exemplified by the Eco-Atkins diet (50). This flexibility allows individualization of dietary choice on a ketogenic diet for obesity and diabetes.

Acknowledgments
The sole author was responsible for all aspects of this manuscript.

References
1. Henderson G. Court of last appeal – the early history of the high-fat diet for diabetes. J Diabetes Metab 2016;7(8):e496.
2. Ludwig DS. Lowering the bar on the low-fat diet. JAMA 2016;316(20):2087–8.
3. Joshi S, Ostfeld RJ, McMacken M. The ketogenic diet for obesity and diabetes—enthusiasm outpaces evidence. JAMA Intern Med 2019;179(7):1163–4.
4. Blundell JE, MacDiarmid JI. Fat as a risk factor for overconsumption: satiation, satiety, and patterns of eating. JADA 1997;97(7 Suppl):563–9.
5. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “calories in, calories out”. JAMA Intern Med 2018;178(8):1098–103.
6. Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA 2014;311(21):2167–8.
7. Bueno NB, de Mello IS, de Oliveira SL, da Rocha Atrado T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr 2013;110(7):1178–87.
8. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic review of the Mediterranean diet for long-term weight loss. J Am Med 2016;129(4):407–15.e4.
9. Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr 2016;115(3):466–79.
10. Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. JAMA Diabetes Endocrinol 2015;3(12):968–79.
11. Cederquist DC, Brewer WD, Waggoner AN, Dunaig D, Ohlson MA. Weight reduction on low-fat and low-carbohydrate diets. J Am Diet Assoc 1952;28(2):113–16.
12. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr 2008;87(1):44–55.
13. Ebbeling CB, Feldman HA, Klein GL, Wong JW, Bieelak L, Steltz SK, Luoto PK, Wolfe RR, Wong WW, Ludwig DS. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. Br Med J 2018;363:k4583.
14. Walsh CO, Ebbeling CB, Swain JF, Markowitz RL, Feldman HA, Ludwig DS. Effects of diet composition on postprandial energy availability during weight loss maintenance. PLoS One 2013;8(3):e58172.
15. Tseng YH, Cypess AM, Kahn CR. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 2010;9(6):465–82.
16. Ludwig DS, Lakin PR, Wong WW, Ebbeling CB. Scientific discourse in the era of open science: a response to Hall et al. regarding the Carbohydrate-Insulin Model. Int J Obes (Lond)[Internet] 2019. doi: 10.1038/s41366-019-0466-1.
17. Hall KD, Guo J. Obesity energetic: body weight regulation and the effects of diet composition. Gastroenterology 2017;152(7):1718–27.e3.
18. Sherrirer M, Li H. The impact of keto-adaptation on exercise performance and the role of metabolic-regulating cytokines. Am J Clin Nutr 2019;110(3):562–73.
19. Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard BV, Larson J, Perri MG, Beresford SA, Robinson JG, Rodriguez B, et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women’s Health Initiative randomized controlled dietary modification trial. Arch Intern Med 2008;168(14):1500–11.
20. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369(2):143–54.
21. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.
22. Evert AB, Dennison M, Gardner CD, Garvey WT, Lai KHK, MacLeod J, Mitri J, Pereira RF, Rawlings K, Robinson S, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42(5):731–54.
23. Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanupri NH, Campbell CW, Volek JS, Phinney SD, McCarter JP. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial. Front Endocrinol (Lausanne) 2019;10:348.
24. Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, Rhodes ET, Ebbeling CB, Westman EC, Yancy WS, Jr, et al. Management of type 1 diabetes with a very low-carbohydrate diet. Pediatrics 2018;141(6):e20173349.
25. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166(3):285–93.
26. Faghihnia N, Tsimikas S, Miller ER, Wittem J, Krauss RM. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 2010;51(11):3224–30.
27. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low-high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104(25):3046–51.
28. Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg BJ, Hugar EC, Black H, Goldberg J. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol 2018;38(9):2207–16.
29. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011;93(5):1048–52.
30. Pepener Y, Shesel I, Komy O, Cohen N, Schwarzfuchs D, Bril N, Rem M, Serfety D, Kenigsbuch S, Zelicha H, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol 2019;71(2):379–88.
31. Hyde PN, Sapper TN, Crabtree CD, LaFountain RA, Bowling ML, Buga A, Fell B, McSwain FT, Dickerson RM, Miller VJ, et al. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI Insight 2019;4(12):128308.
32. Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, Rasane SM, Lee S, Mancina RM, Bergentall M, Pietiläinen KH, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab 2018;27(3):539–71.e5.
33. Volek JS, Phinney SD, Forsythe CE, Quann EE, Ballantyne CM, Olsson AG, Cook TJ, LaFountain RA, Bowling ML, Buga A, Fell B, McSwain FT, Dickerson RM, Miller VJ, et al. Effects of dietary carbohydrate restriction on hepatic steatosis in humans. Cell Metab 2018;27(3):539–71.e5.
34. Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, Kraemer WJ, Bibus DM, Fernandez ML, Feinman RD. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low-fat diet. Lipids 2009;44(4):297–309.
35. Westman EC, Yancy WS, Jr, Olsen MK, Dudley T, Guyton JR, Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. Int J Cardiol 2006;110(2):212–16.
36. Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, Willett WC, Hu FB, Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med 2016;176(8):1134–45.
37. Forsythe CE, Phinney SD, Feinman RD, Volk BM, Fredenreich D, Quann E, Ballard K, Puglisi MJ, Maresch CM, Kraemer WJ, et al. Limited effect of dietary saturated fat on plasma saturated fat in the context of a low carbohydrate diet. Lipids 2010;45(10):947–62.
37. Volk BM, Kunces LJ, Freidenreich DJ, Kupchak BR, Saenz C, Artistizabal JC, Fernandez ML, Bruno RS, Maresh CM, Kraemer WJ, et al. Effects of step-wise increases in dietary carbohydrate on circulating saturated fatty acids and palmitoleic acid in adults with metabolic syndrome. PLoS One 2014;9(11):e113605.

38. Ludwig DS, Willett WC, Volek JS, Neuhaus ML. Dietary fat: from foe to friend? Science 2018;362(6416):764–70.

39. Cahill GF, Jr, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003;114:149–61; discussion 62–3.

40. Kraus H, Schlenker S, Schwedesky D. Developmental changes of cerebral ketone body utilization in human infants. Hoppe Seylers Z Physiol Chem 1974;355(2):164–70.

41. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014;35(3):515–27.

42. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer – where do we stand? Mol Metab [Internet] 2019. doi: 10.1016/j.molmet.2019.06.026.

43. Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 2018;560(7719):499–503.

44. Ota M, Matsuo J, Ishida I, Takano H, Yokoi Y, Hori H, Yoshida S, Ashida K, Nakamura K, Takahashi T, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer's disease. Neurosci Lett 2019;690:232–6.

45. Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease. Alzheimers Dement (NY) 2018;4:28–36.

46. Wing RR, Vazquez JA, Ryan CM. Cognitive effects of ketogenic weight-reducing diets. Int J Obes Relat Metab Disord 1995;19(11):811–16.

47. Brietzke E, Mansur RB, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A, Rosenblat JD, Ho R, McIntyre RS. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev 2018;94:11–16.

48. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. Br Med J 2016;353:i2716.

49. Sadeghi O, Sadeghian M, Rahmani S, Maleki V, Larijani B, Esmaillzadeh A. Whole-grain consumption does not affect obesity measures: an updated systematic review and meta-analysis of randomized clinical trials. Adv Nutr 2019;11(2):280–92.

50. Jenkins DJ, Wong JM, Kendall CW, Esfahani A, Ng VW, Leong TC, Faulkner DA, Vidgen E, Greaves KA, Paul G, et al. The effect of a plant-based low-carbohydrate (“Eco-Atkins”) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med 2009;169(11):1046–54.